{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:12:04Z","timestamp":1780819924257,"version":"3.54.1"},"reference-count":96,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Though antimicrobial stewardship programs (ASPs) are required for hospitals, the involvement of transplant recipients in programmatic interventions, protocols, and metrics has historically been limited. Though there is a growing interest in studying stewardship practices in transplant patients, optimal practices have not been clearly established. A component of ASPs, antiviral stewardship (AVS), specifically targeting cytomegalovirus (CMV), has been more recently described. Understanding AVS opportunities and interventions is particularly important for transplant recipients, given the morbidity and mortality associated with viral infections, challenging clinical syndromes, ultrasensitive molecular diagnostic assays, antiviral resistance, and costs of viral disease and medications, as well as antiviral drug toxicities. This review highlights opportunities for AVS for CMV, EBV, HSV, VZV, SARS-CoV-2, respiratory syncytial virus, and BK polyomavirus in transplant patients.<\/jats:p>","DOI":"10.3390\/v16121884","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T04:13:03Z","timestamp":1733371983000},"page":"1884","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antiviral Stewardship in Transplantation"],"prefix":"10.3390","volume":"16","author":[{"given":"Sruthi","family":"Bonda","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Ochsner Medical Center, New Orleans, LA 70115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Trinh","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Ochsner Medical Center, New Orleans, LA 70115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Hand","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Ochsner Medical Center, New Orleans, LA 70115, USA"},{"name":"Ochsner Clinical School, University of Queensland School of Medicine, New Orleans, LA 70115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/ajt.16743","article-title":"White paper on antimicrobial stewardship in solid organ transplant recipients","volume":"22","author":"So","year":"2022","journal-title":"Am. J. Transplant."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3324\/haematol.2013.091769","article-title":"The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients","volume":"98","author":"Gyssens","year":"2013","journal-title":"Haematologica"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e13864","DOI":"10.1111\/tid.13864","article-title":"Cytomegalovirus antiviral stewardship in solid organ transplant recipients: A new gold standard","volume":"24","author":"Jorgenson","year":"2022","journal-title":"Transpl. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1017\/ice.2020.203","article-title":"The development and implementation of stewardship initiatives to optimize the prevention and treatment of cytomegalovirus infection in solid-organ transplant recipients","volume":"41","author":"Jorgenson","year":"2020","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_5","first-page":"2062","article-title":"How I prevent viral reactivation in high-risk patients","volume":"141","author":"Dadwal","year":"2023","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bbmt.2006.08.040","article-title":"Treatment of adenovirus disease in stem cell transplant recipients with cidofovir","volume":"13","author":"Neofytos","year":"2007","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1182\/blood-2012-04-421412","article-title":"How I treat HHV8\/KSHV-related diseases in posttransplant patients","volume":"120","author":"Riva","year":"2012","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e13443","DOI":"10.1111\/tid.13443","article-title":"Retrospective case analysis of antiviral therapies for HHV-6 encephalitis after hematopoietic stem cell transplantation","volume":"23","author":"Toomey","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/cid\/cit639","article-title":"Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: Viral RNA detection in blood, antiviral treatment, and clinical outcomes","volume":"57","author":"Waghmare","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/cid\/cix259","article-title":"Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients","volume":"65","author":"Fisher","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"ofad018","DOI":"10.1093\/ofid\/ofad018","article-title":"Cytomegalovirus DNAemia Requiring (Val)Ganciclovir Treatment for More Than 8 Weeks Is a Key Factor in the Development of Antiviral Drug Resistance","volume":"10","author":"Acquier","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/infdis\/jiad293","article-title":"Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients","volume":"229","author":"Chou","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e13515","DOI":"10.1111\/tid.13515","article-title":"Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature","volume":"23","author":"Hofmann","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jama.2020.3138","article-title":"Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients with Seropositive Donors: A Randomized Clinical Trial","volume":"323","author":"Singh","year":"2020","journal-title":"JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/infdis\/jiz181","article-title":"Prospective Assessment of Cytomegalovirus Immunity in High-Risk Donor-Seropositive\/Recipient-Seronegative Liver Transplant Recipients Receiving Either Preemptive Therapy or Antiviral Prophylaxis","volume":"220","author":"Limaye","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/cid\/ciad643","article-title":"Association of Cytomegalovirus (CMV) DNAemia with Long-Term Mortality in a Randomized Trial of Preemptive Therapy and Antiviral Prophylaxis for Prevention of CMV Disease in High-Risk Donor Seropositive, Recipient Seronegative Liver Transplant Recipients","volume":"78","author":"Kumar","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial","volume":"330","author":"Limaye","year":"2023","journal-title":"JAMA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e14337","DOI":"10.1111\/tid.14337","article-title":"Use of letermovir for cytomegalovirus primary prophylaxis in lung transplant recipients","volume":"26","author":"Kleiboeker","year":"2024","journal-title":"Transpl. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e15327","DOI":"10.1111\/ctr.15327","article-title":"Real-life use of letermovir prophylaxis for cytomegalovirus in heart transplant recipients","volume":"38","author":"Saltiel","year":"2024","journal-title":"Clin. Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/jcph.1423","article-title":"Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil","volume":"59","author":"McCrea","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/jac\/dkz499","article-title":"Clinically significant drug interaction: Letermovir and voriconazole","volume":"75","author":"Duong","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/TP.0000000000001338","article-title":"Recurrence of CMV Infection and the Effect of Prolonged Antivirals in Organ Transplant Recipients","volume":"101","author":"Natori","year":"2017","journal-title":"Transplantation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/TP.0000000000000386","article-title":"The role of secondary cytomegalovirus prophylaxis for kidney and liver transplant recipients","volume":"99","author":"Sullivan","year":"2015","journal-title":"Transplantation"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/lt.24332","article-title":"Characteristics and outcomes of neutropenia after orthotopic liver transplantation","volume":"22","author":"Alraddadi","year":"2016","journal-title":"Liver Transpl."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1182\/blood.V97.2.388","article-title":"Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation","volume":"97","author":"Ljungman","year":"2001","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e15480","DOI":"10.1111\/ctr.15480","article-title":"Evaluating Real-World Experience With Maribavir for Treatment of Refractory\/Resistant Cytomegalovirus in Renal Transplant Recipients","volume":"38","author":"Beechar","year":"2024","journal-title":"Clin. Transplant."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1093\/cid\/ciw118","article-title":"Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"Barlam","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/j.1600-6143.2007.01910.x","article-title":"Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients","volume":"7","author":"Asberg","year":"2007","journal-title":"Am. J. Transplant."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40780-024-00352-y","article-title":"A case of successful contribution of therapeutic drug monitoring of valganciclovir as the prophylaxis against cytomegalovirus infection in a lung transplant recipient","volume":"10","author":"Katada","year":"2024","journal-title":"J. Pharm. Health Care Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e12991","DOI":"10.1111\/tid.12991","article-title":"A pharmacist-driven antimicrobial stewardship intervention targeting cytomegalovirus viremia in ambulatory solid organ transplant recipients","volume":"20","author":"Wang","year":"2018","journal-title":"Transpl. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/ajt.15315","article-title":"A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients","volume":"19","author":"Kumar","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1111\/ajt.14347","article-title":"An Interventional Study Using Cell-Mediated Immunity to Personalize Therapy for Cytomegalovirus Infection After Transplantation","volume":"17","author":"Kumar","year":"2017","journal-title":"Am. J. Transplant."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: A CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jtct.2021.05.001","article-title":"American Society for Transplantation and Cellular Therapy Series: #3-Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation","volume":"27","author":"Hakki","year":"2021","journal-title":"Transplant. Cell Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40506-021-00253-w","article-title":"CMV Infection in Hematopoietic Stem Cell Transplantation: Prevention and Treatment Strategies","volume":"13","author":"Jakharia","year":"2021","journal-title":"Curr. Treat. Options Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"792.e1","DOI":"10.1016\/j.jtct.2024.05.021","article-title":"Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral Therapy for Cytomegalovirus on Economic and Clinical Outcomes after Hematopoietic Cell Transplantation","volume":"30","author":"Tan","year":"2024","journal-title":"Transplant. Cell Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1093\/cid\/ciz1210","article-title":"Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study","volume":"71","author":"Chemaly","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"874601","DOI":"10.1155\/2012\/874601","article-title":"Improving safety of preemptive therapy with oral valganciclovir for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation","volume":"2012","author":"Barkam","year":"2012","journal-title":"Bone Marrow Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.V99.4.1159","article-title":"Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation","volume":"99","author":"Reusser","year":"2002","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3851\/IMP1858","article-title":"Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients","volume":"16","author":"Len","year":"2011","journal-title":"Antivir. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood-2005-09-3786","article-title":"Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation","volume":"107","author":"Einsele","year":"2006","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/cid\/ciad709","article-title":"Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir","volume":"78","author":"Papanicolaou","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e14216","DOI":"10.1111\/tid.14216","article-title":"Cytomegalovirus related hospitalization costs among hematopoietic stem cell and solid organ transplant recipients treated with maribavir versus investigator-assigned therapy: A US-based study","volume":"26","author":"Schultz","year":"2024","journal-title":"Transpl. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/bloodadvances.2017010223","article-title":"Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells","volume":"1","author":"Withers","year":"2017","journal-title":"Blood Adv."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.bbmt.2018.08.024","article-title":"Establishment and Operation of a Third-Party Virus-Specific T Cell Bank within an Allogeneic Stem Cell Transplant Program","volume":"24","author":"Withers","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/bmt.2016.17","article-title":"Virus-specific T-cell banks for \u2018off the shelf\u2019 adoptive therapy of refractory infections","volume":"51","author":"Prockop","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jtct.2023.09.018","article-title":"American Society of Transplantation and Cellular Therapy Series: #7\u2014Management of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients","volume":"29","author":"Kaul","year":"2023","journal-title":"Transplant. Cell Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e13511","DOI":"10.1111\/ctr.13511","article-title":"RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Manuel","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/infdis\/jit832","article-title":"Respiratory syncytial virus in hematopoietic cell transplant recipients: Factors determining progression to lower respiratory tract disease","volume":"209","author":"Kim","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1093\/cid\/ciab969","article-title":"Respiratory Syncytial Virus, Human Metapneumovirus, and Parainfluenza Virus Infections in Lung Transplant Recipients: A Systematic Review of Outcomes and Treatment Strategies","volume":"74","author":"Lunter","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1182\/blood-2013-12-541359","article-title":"Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections","volume":"123","author":"Shah","year":"2014","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/jac\/dkt111","article-title":"Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections","volume":"68","author":"Shah","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1399-3062.2009.00453.x","article-title":"A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients","volume":"12","author":"Liu","year":"2010","journal-title":"Transpl. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1086\/509930","article-title":"Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients","volume":"44","author":"Boeckh","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/sj.bmt.1702228","article-title":"Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: Combination therapy with aerosolized ribavirin and intravenous immunoglobulin","volume":"25","author":"Ghosh","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/cid\/ciy760","article-title":"Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients","volume":"68","author":"Foolad","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.healun.2015.01.009","article-title":"Oral ribavirin for respiratory syncytial virus infection after lung transplantation: Efficacy and cost-efficiency","volume":"34","author":"Burrows","year":"2015","journal-title":"J. Heart Lung Transplant."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"793","DOI":"10.15585\/mmwr.mm7229a4","article-title":"Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023","volume":"72","author":"Melgar","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults","volume":"388","author":"Papi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults","volume":"388","author":"Walsh","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e2342006","DOI":"10.1001\/jamanetworkopen.2023.42006","article-title":"COVID-19 Hospitalization in Solid Organ Transplant Recipients on Immunosuppressive Therapy","volume":"6","author":"Kolla","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.ajt.2024.03.011","article-title":"Longitudinal outcomes of COVID-19 in solid organ transplant recipients from 2020 to 2023","volume":"24","author":"Solera","year":"2024","journal-title":"Am. J. Transplant."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1108.e1101","DOI":"10.1016\/j.jtct.2024.09.019","article-title":"COVID-19 Outcomes Among Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Recipients in the Era of SARS-CoV-2 Omicron Variants and COVID-19 Therapeutics","volume":"30","author":"Rosen","year":"2024","journal-title":"Transplant. Cell Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e2435431","DOI":"10.1001\/jamanetworkopen.2024.35431","article-title":"Emerging SARS-CoV-2 Resistance After Antiviral Treatment","volume":"7","author":"Tamura","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/ajt.17199","article-title":"Short-course early outpatient remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the omicron BA.2 wave","volume":"23","author":"Solera","year":"2023","journal-title":"Am. J. Transplant."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1097\/TP.0000000000004588","article-title":"Molnupiravir for Treatment of COVID-19 in Solid Organ Transplant Recipients","volume":"107","author":"Dhand","year":"2023","journal-title":"Transplantation"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e14037","DOI":"10.1111\/tid.14037","article-title":"Saving lives with nirmatrelvir\/ritonavir one transplant patient at a time","volume":"25","author":"Belden","year":"2023","journal-title":"Transpl. Infect. Dis."},{"key":"ref_76","unstructured":"Bhimraj, A., Morgan, R.L., Shumaker, A.H., Lavergne, V., Baden, L., Cheng, V.C., Edwards, K.M., Gandhi, R., Muller, W.J., and O\u2019Horo, J.C. (2024). Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin. Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jtct.2022.09.002","article-title":"Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)","volume":"28","author":"Dioverti","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"100788","DOI":"10.1016\/j.trre.2023.100788","article-title":"Executive summary of the consensus statement of the group for the study of infection in transplantation and other immunocompromised host (GESITRA-IC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the treatment of SARS-CoV-2 infection in solid organ transplant recipients","volume":"37","author":"Herrera","year":"2023","journal-title":"Transplant. Rev."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e13526","DOI":"10.1111\/ctr.13526","article-title":"Herpes simplex virus infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Lee","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1086\/518938","article-title":"Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: Impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease","volume":"196","author":"Erard","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"882","DOI":"10.6004\/jnccn.2016.0093","article-title":"Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Baden","year":"2016","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Broadhurst, M.J., Dujari, S., Budvytiene, I., Pinsky, B.A., Gold, C.A., and Banaei, N. (2020). Utilization, Yield, and Accuracy of the FilmArray Meningitis\/Encephalitis Panel with Diagnostic Stewardship and Testing Algorithm. J. Clin. Microbiol., 58.","DOI":"10.1128\/JCM.00311-20"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Markovich, K., Wingler, M.J.B., Stover, K.R., Barber, K.E., Wagner, J.L., and Cretella, D.A. (2022). Analysis of the Clinical Impact of the BioFire FilmArray Meningitis Encephalitis Panel on Antimicrobial Use and Duration of Therapy at an Academic Medical Center. Diseases, 10.","DOI":"10.3390\/diseases10040110"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cmi.2019.11.016","article-title":"Diagnostic test accuracy of the BioFire(R) FilmArray(R) meningitis\/encephalitis panel: A systematic review and meta-analysis","volume":"26","author":"Tansarli","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3324\/haematol.2016.144428","article-title":"Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines","volume":"101","author":"Styczynski","year":"2016","journal-title":"Haematologica"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e13652","DOI":"10.1111\/ctr.13652","article-title":"Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Allen","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Rosemarie, Q., and Sugden, B. (2020). Epstein-Barr Virus: How Its Lytic Phase Contributes to Oncogenesis. Microorganisms, 8.","DOI":"10.3390\/microorganisms8111824"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Lupo, J., Wielandts, A.S., Buisson, M., Consortium, C., Habib, M., Hamoudi, M., Morand, P., Verduyn-Lunel, F., Caillard, S., and Drouet, E. (2022). High Predictive Value of the Soluble ZEBRA Antigen (Epstein-Barr Virus Trans-Activator Zta) in Transplant Patients with PTLD. Pathogens, 11.","DOI":"10.3390\/pathogens11080928"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Tan, H., Gong, Y., Liu, Y., Long, J., Luo, Q., Faleti, O.D., and Lyu, X. (2023). Advancing therapeutic strategies for Epstein-Barr virus-associated malignancies through lytic reactivation. Biomed. Pharmacother., 164.","DOI":"10.1016\/j.biopha.2023.114916"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/j.1600-6143.2008.02269.x","article-title":"Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression","volume":"8","author":"Bernhoff","year":"2008","journal-title":"Am. J. Transplant."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1097\/TP.0000000000004976","article-title":"The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation","volume":"108","author":"Kotton","year":"2024","journal-title":"Transplantation"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1001\/jama.2014.14721","article-title":"Levofloxacin for BK virus prophylaxis following kidney transplantation: A randomized clinical trial","volume":"312","author":"Knoll","year":"2014","journal-title":"JAMA"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1111\/ajt.15328","article-title":"Ciprofloxacin for BK viremia prophylaxis in kidney transplant recipients: Results of a prospective, double-blind, randomized, placebo-controlled trial","volume":"19","author":"Patel","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.kjms.2016.01.004","article-title":"Fluoroquinolone prophylaxis in preventing BK polyomavirus infection after renal transplant: A systematic review and meta-analysis","volume":"32","author":"Song","year":"2016","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/bloodadvances.2019000802","article-title":"Presentation of BK polyomavirus-associated hemorrhagic cystitis after allogeneic hematopoietic cell transplantation","volume":"4","author":"Imlay","year":"2020","journal-title":"Blood Adv."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1017\/ice.2016.149","article-title":"Current State of Antimicrobial Stewardship at Solid Organ and Hematopoietic Cell Transplant Centers in the United States","volume":"37","author":"Seo","year":"2016","journal-title":"Infect. Control Hosp. Epidemiol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/12\/1884\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:47:20Z","timestamp":1760114840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/12\/1884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":96,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["v16121884"],"URL":"https:\/\/doi.org\/10.3390\/v16121884","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]}}}